Liraglutide lowered body mass, slowed weight gain and improved health markers in kids ages 6 through 11, according to ...
The Clinical Trials Arena team investigates assets in infectious diseases, metabolic disorders, oncology and ophthalmology.
The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...
Liraglutide treatment significantly lowers BMI in obese children aged 6 to <12, but gastrointestinal side effects prompt the ...
Currently, there are no approved medications for treating nonmonogenic, nonsyndromic obesity in children under 12. While ...
Liraglutide is the first GLP-1 agonist to show benefit in this age group and could provide young patients a much-needed ...
In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s ...
Evidence shows that blockbuster weight-loss medications can reduce obesity even in children aged 6–11, but their long-term ...